Metacrine Inc. (MTCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
MTCR Stock Price Chart Interactive Chart >
MTCR Price/Volume Stats
| Current price | $3.07 | 52-week high | $11.65 |
| Prev. close | $3.12 | 52-week low | $2.59 |
| Day low | $3.02 | Volume | 192,600 |
| Day high | $3.17 | Avg. volume | 139,132 |
| 50-day MA | $3.00 | Dividend yield | N/A |
| 200-day MA | $5.66 | Market Cap | 81.43M |
Metacrine Inc. (MTCR) Company Bio
Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.
Latest MTCR News From Around the Web
Below are the latest news stories about Metacrine Inc that investors may wish to consider to help them evaluate MTCR as an investment opportunity.
Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With NashExceeded enrollment target of 180 total patientsInterim data from the first 60 patients expected early in the fourth quarter of 2021Topline MET642 trial results from all patients are anticipated in the first half of 2022 SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it has completed enrollment for its Phase 2a tr |
Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021Featuring KOL and management discussions on the science of FXR agonists and the Company’s programs in NASH and IBD SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced it will host a virtual R&D Day for analysts and investors on Wednesday, September 15, 2021 at 12:00 p.m. ET. The event will showcase Metacrine’s programs in n |
Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceSAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 a.m. ET on Monday, September 13, 2021. A webcast of the presentation will be available at https://investor |
Metacrine Updates MET642 Clinical Development Milestone and Reports Second-Quarter 2021 ResultsInterim data from the Phase 2a trial of MET642 in patients with NASH now expected early in the fourth quarter of 2021Topline results from a Phase 2a trial of MET409 in combination with empagliflozin in patients with NASH and type 2 diabetes on track to be reported in the fourth quarter of 2021 SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal disea |
Metacrine to Present at 2021 Canaccord Genuity Growth ConferenceSAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021. A live webcast of the presentation will be available at https://investors.metacrine. |
MTCR Price Returns
| 1-mo | 9.25% |
| 3-mo | -21.28% |
| 6-mo | -56.14% |
| 1-year | -69.60% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -60.94% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...